Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy
Abstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-021-01787-5 |
id |
doaj-fea2961a79a34cda82cbcc74bf8fccf8 |
---|---|
record_format |
Article |
spelling |
doaj-fea2961a79a34cda82cbcc74bf8fccf82021-05-11T14:51:55ZengBMCBMC Gastroenterology1471-230X2021-05-0121111410.1186/s12876-021-01787-5Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathyYing Zhu0Wen Xu1Wei Hu2Fang Wang3Yan Zhou4Jianguo Xu5Wei Gong6Department of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityInformation Management Section, Bethune International Peace HospitalDepartment of Liver Disease Center, Shenzhen Hospital of Southern Medical UniversityDepartment of Gastroenterology, Shenzhen Hospital of Southern Medical UniversityAbstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified. Methods We conducted a pilot study consisting of 5 portal hypertensive gastropathy (PHG) patients and 5 normal controls, sampling the gastric mucosa of normal controls and PHG patients before and after endoscopic cyanoacrylate injection, using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in gastric mucosa from PHG patients and normal controls. Then we further used parallel reaction monitoring (PRM) to verify the abundance of the targeted protein. Results LFQ analyses identified 423 significantly differentially expressed proteins. 17 proteins that significantly elevated in the gastric mucosa of PHG patients were further validated using PRM. Conclusions This is the first application of an LFQ-PRM workflow to identify and validate PHG–specific biomarkers in patient gastric mucosa samples. Our findings lay the foundation for comprehending the molecular mechanisms of PHG pathogenesis, and provide potential applications for useful biomarkers in early diagnosis and treatment. Trial registration and ethics approval: Trial registration was completed (ChiCTR2000029840) on February 25, 2020. Ethics Approvals were completed on July 17, 2017 (NYSZYYEC20180003) and February 15, 2020 (NYSZYYEC20200005).https://doi.org/10.1186/s12876-021-01787-5BiomarkerLabel-free quantitative mass spectrometryLiver cirrhosisParallel reaction monitoringPortal hypertension gastropathyProteomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ying Zhu Wen Xu Wei Hu Fang Wang Yan Zhou Jianguo Xu Wei Gong |
spellingShingle |
Ying Zhu Wen Xu Wei Hu Fang Wang Yan Zhou Jianguo Xu Wei Gong Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy BMC Gastroenterology Biomarker Label-free quantitative mass spectrometry Liver cirrhosis Parallel reaction monitoring Portal hypertension gastropathy Proteomics |
author_facet |
Ying Zhu Wen Xu Wei Hu Fang Wang Yan Zhou Jianguo Xu Wei Gong |
author_sort |
Ying Zhu |
title |
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
title_short |
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
title_full |
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
title_fullStr |
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
title_full_unstemmed |
Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
title_sort |
discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy |
publisher |
BMC |
series |
BMC Gastroenterology |
issn |
1471-230X |
publishDate |
2021-05-01 |
description |
Abstract Background Portal hypertension induced esophageal and gastric variceal bleeding is the main cause of death among patients of decompensated liver cirrhosis. Therefore, a standardized, biomarker-based test, to make an early-stage non-invasive risk assessment of portal hypertension, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified. Methods We conducted a pilot study consisting of 5 portal hypertensive gastropathy (PHG) patients and 5 normal controls, sampling the gastric mucosa of normal controls and PHG patients before and after endoscopic cyanoacrylate injection, using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in gastric mucosa from PHG patients and normal controls. Then we further used parallel reaction monitoring (PRM) to verify the abundance of the targeted protein. Results LFQ analyses identified 423 significantly differentially expressed proteins. 17 proteins that significantly elevated in the gastric mucosa of PHG patients were further validated using PRM. Conclusions This is the first application of an LFQ-PRM workflow to identify and validate PHG–specific biomarkers in patient gastric mucosa samples. Our findings lay the foundation for comprehending the molecular mechanisms of PHG pathogenesis, and provide potential applications for useful biomarkers in early diagnosis and treatment. Trial registration and ethics approval: Trial registration was completed (ChiCTR2000029840) on February 25, 2020. Ethics Approvals were completed on July 17, 2017 (NYSZYYEC20180003) and February 15, 2020 (NYSZYYEC20200005). |
topic |
Biomarker Label-free quantitative mass spectrometry Liver cirrhosis Parallel reaction monitoring Portal hypertension gastropathy Proteomics |
url |
https://doi.org/10.1186/s12876-021-01787-5 |
work_keys_str_mv |
AT yingzhu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT wenxu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT weihu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT fangwang discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT yanzhou discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT jianguoxu discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy AT weigong discoveryandvalidationofnovelproteinmarkersinmucosaofportalhypertensivegastropathy |
_version_ |
1721443950870396928 |